Cell-Easy Signs Groundbreaking Manufacturing Contract, Paving the Way for Local Hospitals to Offer Next-Generation CAR-T Therapy
Toulouse, France, march 26, 2024 – This agreement with a pioneer European C&G company will soon enable the initiation of new clinical trials in South of France based on innovative CAR-T cell treatments
The French Contract Development and Manufacturing Organization (CDMO) Cell-Easy stands out and achieves a new milestone by
securing a service contract aimed at producing multiple autologous CAR-T cell-based treatments. The biocluster recently formed by
Toulouse players (MoU signed between Cell-Easy and the Oncopole Claudius Régaud, OCR) is already bearing fruit and will enable
patients with certain forms of liquid cancer to access new generations of CAR-T cell therapies.
Advancements in CAR-T cell therapies have been swift, with approvals granted for a spectrum of applications. Notably, these therapies have demonstrated exceptional efficacy in combatting certain blood cancers. Nevertheless, developers of autologous CAR- T cell therapies must adapt their strategies to account for complexities in regulatory pathways, patient access, and manufacturing/logistic processes.
Collaboration with strategic partners, including CDMOs and healthcare providers, can provide CAR-T cell developers with expertise, resources, and infrastructure to accelerate clinical trials initiation while managing costs. The Toulouse-based CDMO Cell-Easy, an expert in the development and manufacturing of cell-based therapies, has been selected for these reasons, notably:
- CMC and Regulatory support.
- Reactivity to manufacture swiftly after patient inclusion.
- Clinician network.
The accumulated expertise among various programs as well as our local partnerships have been the foundation to close such a deal. I’m a true believer that our positioning can be beneficial for other biotech seeking to easily access patient cohorts.
About Cell-Easy
Cell-Easy is a science-centric CDMO specialized on advanced Cell Therapies. Cell-Easy offers a broad range of Services, including Process and Analytical development, GMP manufacturing and CMC/Regulatory support for global Biotechs & Pharmas. The scientific team and QbD approach enable seamless technology transfer and development for cell-based therapies in the fields of oncology, autoimmunity, and
regenerative medicine (T cells, NK cells, Macrophages, MSCs, HSCs and exosomes) Explore our services at www.cell-easy.com and don’t hesitate to contact us at info@cell-easy.com
About OCR
The IUCT-Oncopole, a cancer care, research and training center in Toulouse, combines the expertise of 1,800 professionals on a single site labeled “Comprehensive Cancer Center”. It includes several state-of-the-art clinical facilities for the treatment of cancer with a world-class research infrastructure, on an integrated campus that brings together public and private stakeholders, including industrial partners. The IUCT-Oncopole, which includes Oncopole Claudius Regaud and several teams from the Toulouse University Hospital (CHU), treats more than 10,000 new patients every year, and more than one in eight patients is enrolled in clinical studies.
